PMID- 24434345
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20221207
IS  - 1827-1898 (Electronic)
IS  - 0031-0808 (Linking)
VI  - 55
IP  - 4
DP  - 2013 Dec
TI  - Plasma brain derived neurotrophic factor levels and neuropsychological aspects of 
      depressed patients treated with paroxetine.
PG  - 377-84
AB  - AIM: Studies on major depressive disorders (MDD) pathophysiology show decreased 
      blood levels of brain-derived neurotrophic factor (BDNF) that increase after 
      antidepressant treatment. The link between BDNF levels and antidepressants is 
      still controversial. In addiction, there is a relationship between MDD and 
      concurrent cognitive function. Hippocampus is linked to memory and learning and 
      BDNF is abundant in this area. For this reason we investigated the presence of 
      any association between paroxetine treatment, BDNF levels and cognitive 
      performances in depressed patients. METHODS: Sixteen patients with MDD were 
      compared with a control group of 18 randomly selected healthy individuals. Blood 
      samples were taken and clinical and neuropsychological assessments were performed 
      at baseline and after two months of treatment. Plasma and serum BDNF levels were 
      measured with the Elisa method. RESULTS: Plasma BDNF levels are lower in 
      depressed patients and increased after treatment. No serum BDNF significant 
      differences were found. Depressed patients showed a mild deficit in prose memory 
      tests that reached normality after antidepressant treatment. No correlations were 
      evidenced between patients plasma BDNF levels and cognitive results. CONCLUSION: 
      To our knowledge this is one of the few studies on the effects of paroxetine 
      treatment on plasma BDNF levels. We confirm literature data regarding the link 
      between BDNF plasma levels, depression and antidepressant treatments. In 
      addiction we found a specific cognitive deficit of depressed patients.
FAU - Munno, D
AU  - Munno D
AD  - Unit of Clinical Psychology Department of Neuroscience University of Turin, 
      Turin, Italy - donato.munno@unito.it.
FAU - Sterpone, S
AU  - Sterpone S
FAU - Fania, S
AU  - Fania S
FAU - Cappellin, F
AU  - Cappellin F
FAU - Mengozzi, G
AU  - Mengozzi G
FAU - Saroldi, M
AU  - Saroldi M
FAU - Bechon, E
AU  - Bechon E
FAU - Zullo, G
AU  - Zullo G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 41VRH5220H (Paroxetine)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Cognition/*drug effects
MH  - Depressive Disorder, Major/blood/diagnosis/*drug therapy/psychology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Memory/drug effects
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Paroxetine/*therapeutic use
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2014/01/18 06:00
MHDA- 2014/07/09 06:00
CRDT- 2014/01/18 06:00
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
AID - R41Y2013N04A0377 [pii]
PST - ppublish
SO  - Panminerva Med. 2013 Dec;55(4):377-84.